Bristol-Myers Squibb Co. said the phase III CheckMate-498 trial evaluating Opdivo (nivolumab) plus radiation vs. temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase-unmethylated glioblastoma multiforme did not meet its primary endpoint of overall survival at final analysis.
Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients.
